Beximco Pharma Reports Strong Q3 and Nine-Month Results: Profit Up 34%

Beximco Pharma Q3 results 2025-26: profit growth is running ahead of sales growth

The short version is this: Beximco Pharmaceuticals has delivered a strong set of third-quarter and nine-month numbers, with profit rising much faster than revenue. For the nine months to 31 March 2026, net sales increased 13.1% to BDT 41,428.0 million, or £256.9 million, while profit after tax jumped 34.0% to BDT 7,048.6 million, or £43.7 million.

That matters because investors do not just want to see more products sold. They want to see those extra sales turning into better profitability and stronger cash generation. On that front, this update looks encouraging.

Key number	Nine months to 31 March 2026	Nine months to 31 March 2025
Net sales	BDT 41,428.0 million / £256.9 million	BDT 36,622.0 million / £235.0 million
Profit after tax	BDT 7,048.6 million / £43.7 million	BDT 5,261.0 million / £33.8 million
Earnings per share	15.56	11.73
Net operating cash flow per share	16.74	9.46

Beximco Pharma sales analysis: Bangladesh domestic sales are doing the heavy lifting

The standout feature in these results is the domestic business. Domestic sales rose 14.4% to BDT 38,459.2 million, or £238.5 million, which comfortably outweighed a 1.2% dip in export sales to BDT 2,968.8 million, or £18.4 million.

For retail investors, that tells you where the engine is. Beximco’s home market is currently powering growth, while overseas sales were slightly soft over the period. That is not a disaster, but it is worth watching because a broader export push usually adds diversification and reduces dependence on one market.

The third quarter alone was still solid, though a touch slower than the nine-month run rate. Q3 net sales increased 8.1% to BDT 13,627.8 million, or £84.5 million, and profit after tax rose 30.6% to BDT 2,254.4 million, or £14.0 million.

That pattern suggests momentum remains good, but not quite as fast as earlier in the year. In plain English, the business is still growing nicely, just at a slightly more measured pace in the latest quarter.

Beximco Pharma margins improve: why profit rose faster than revenue

This is where the numbers get more interesting. Gross profit rose to BDT 20,309.9 million from BDT 16,799.2 million, meaning gross margin improved to roughly 49.0% from about 45.9%.

That is a meaningful jump. It suggests Beximco kept a better share of each Taka of sales after production costs, even though cost of goods sold still increased to BDT 21,118.1 million.

Operating profit also improved strongly, rising to BDT 9,572.0 million from BDT 7,511.1 million. That puts the operating margin at roughly 23.1%, up from around 20.5% a year earlier.

There is one slight catch. Operating expenses rose to BDT 10,737.9 million from BDT 9,288.1 million, with selling, marketing and distribution expenses up to BDT 9,604.4 million. So the company is spending more to support growth, which is normal enough, but it is still something investors should keep an eye on.

The other big helper was finance cost, which fell sharply to BDT 519.6 million from BDT 802.6 million. Lower finance costs gave profit an extra push, and that is exactly the sort of improvement shareholders like because it feeds straight through to the bottom line.

As a result, profit after tax margin improved to roughly 17.0% from about 14.4%. That is the kind of gap that makes a results statement feel genuinely strong rather than merely respectable.

Beximco Pharma cash flow and balance sheet: stronger cash, lower short-term borrowings

Good accounting profit is nice. Good cash flow is better. Here, Beximco has both.

Net cash generated from operating activities increased to BDT 7,466.1 million from BDT 4,220.8 million. That is a big improvement and suggests the company is converting its profits into cash more effectively than last year.

Cash and cash equivalents climbed to BDT 4,227.6 million from BDT 1,700.1 million at 30 June 2025. That is a sizeable increase, especially when you remember the group was also investing in the business and reducing debt.

On investing activity, Beximco spent BDT 2,664.5 million on property, plant and equipment and BDT 282.8 million on intangible assets. In other words, it is still putting money back into the business rather than simply harvesting profits.

The balance sheet also looks firmer. Total equity increased to BDT 64,096.2 million from BDT 57,084.6 million, while total liabilities fell to BDT 14,635.1 million from BDT 16,162.6 million.

Short-term borrowings dropped to BDT 973.6 million from BDT 2,025.4 million, and current maturities of long-term borrowings fell to BDT 891.6 million from BDT 1,436.8 million. That helps explain the lower finance cost and gives the business a bit more breathing room.

Beximco Pharma Q3 risks and weaker spots: export sales and quarterly slowdown deserve attention

These results are good, but they are not spotless. Export sales slipped 1.2% over the nine-month period, and the latest quarter’s sales growth of 8.1% was slower than the nine-month growth rate of 13.1%.

That does not overturn the positive story, but it does stop this from being a perfect report card. If export growth remains weak, investors may ask whether Beximco is leaning too heavily on domestic demand.

There are also a few line items that rose meaningfully, including inventories at BDT 14,225.7 million from BDT 13,586.5 million and loans, advances, deposits and prepayments at BDT 3,528.3 million from BDT 2,814.5 million. Those increases are not necessarily a problem, but the announcement does not provide extra detail, so there is not much more to say beyond noting them.

It is also worth saying that this announcement does not give full-year guidance. Any detailed operational outlook is not disclosed here, with the company instead pointing readers to a separate announcement released the same day.

What Beximco Pharmaceuticals results mean for retail investors

My view is that this is a positive update. Sales are rising, margins are improving, finance costs are falling, cash generation is much better, and the balance sheet is moving in the right direction.

The biggest positive is quality of earnings. Profit growth was not driven by one odd item buried in the footnotes. It came from a mix of stronger sales, better gross profitability and lower finance cost, which is a healthier recipe.

The main negative is that export sales were weaker and Q3 revenue growth slowed a little. That does not ruin the story, but it means investors should not assume every growth line will keep accelerating from here.

Overall, though, this RNS reads like the kind of update long-term shareholders would want to see. Beximco Pharma appears to be executing well in its core market, generating more cash, and carrying less short-term funding pressure. On the evidence in this announcement alone, that is a solid combination.